 |
 |
To Charles Murray and Benjamin Winter: To the statement that "Research suggested starting with Sinemet was unwise if an agonist would work," I would only comment that it is important to ask what kind of research. If you are talking about MARKET research, then it is certainly unwise to start with levodopa if you own stock in any one of the companies that make the agonists. Remember that the data used to promote the agonists is being pitted against 30 years of good experience with levodopa. There is not a single drug used to treat Parkinson's that has the safety and efficacy record that levodopa has when used correctly. Jorge Romero, MD ----- Original Message ----- From: "Benjamin Winter" <[log in to unmask]> To: <[log in to unmask]> Sent: Friday, June 02, 2000 10:26 PM Subject: questions for Charles Murray > Charles, > > You wrote: > "Research suggested starting with Sinemet was unwise if an > agonist would work ... and studies seem to be showing that > this is a wise way to start treatment in mild cases." > > I would appreciate some leads to the research, some > references to the studies, that you are referring to. > > Thanks in advance. > > Ben Winter 66/66/64 > Not on any meds yet - the great weather in Victoria BC is > enough to keep me going (for now). >